Current status of beta-thalassemia and its treatment strategies.
blood transfusion
chelation therapy
gene therapy
hemoglobin
iron overload
reactive oxygen species
splenectomy
thalassemia
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
15
05
2020
received:
24
01
2020
accepted:
13
08
2021
pubmed:
6
11
2021
medline:
24
3
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Thalassemia is an inherited hematological disorder categorized by a decrease or absence of one or more of the globin chains synthesis. Beta-thalassemia is caused by one or more mutations in the beta-globin gene. The absence or reduced amount of beta-globin chains causes ineffective erythropoiesis which leads to anemia. Beta-thalassemia has been further divided into three main forms: thalassemia major, intermedia, and minor/silent carrier. A more severe form among these is thalassemia major in which individuals depend upon blood transfusion for survival. The high level of iron deposition occurs due to regular blood transfusion therapy. Overloaded iron raises the synthesis of reactive oxygen species (ROS) that are noxious and prompting the injury to the hepatic, endocrine, and vascular system. Thalassemia can be analyzed and diagnosed via prenatal testing (genetic testing of amniotic fluid), blood smear, complete blood count, and DNA analysis (genetic testing). Treatment of thalassemia intermediate is symptomatic; however; it can also be accomplished by folic supplementation and splenectomy. Thalassemia major can be cured through regular transfusion of blood, transplantation of bone marrow, iron chelation management, hematopoietic stem cell transplantation, stimulation of fetal hemoglobin production, and gene therapy.
Sections du résumé
BACKGROUND
Thalassemia is an inherited hematological disorder categorized by a decrease or absence of one or more of the globin chains synthesis. Beta-thalassemia is caused by one or more mutations in the beta-globin gene. The absence or reduced amount of beta-globin chains causes ineffective erythropoiesis which leads to anemia.
METHODS
Beta-thalassemia has been further divided into three main forms: thalassemia major, intermedia, and minor/silent carrier. A more severe form among these is thalassemia major in which individuals depend upon blood transfusion for survival. The high level of iron deposition occurs due to regular blood transfusion therapy.
RESULTS
Overloaded iron raises the synthesis of reactive oxygen species (ROS) that are noxious and prompting the injury to the hepatic, endocrine, and vascular system. Thalassemia can be analyzed and diagnosed via prenatal testing (genetic testing of amniotic fluid), blood smear, complete blood count, and DNA analysis (genetic testing). Treatment of thalassemia intermediate is symptomatic; however; it can also be accomplished by folic supplementation and splenectomy.
CONCLUSION
Thalassemia major can be cured through regular transfusion of blood, transplantation of bone marrow, iron chelation management, hematopoietic stem cell transplantation, stimulation of fetal hemoglobin production, and gene therapy.
Identifiants
pubmed: 34738740
doi: 10.1002/mgg3.1788
pmc: PMC8683628
doi:
Substances chimiques
beta-Globins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1788Informations de copyright
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Annu Rev Med. 2011;62:347-60
pubmed: 20887198
Hum Mutat. 2007 Feb;28(2):206
pubmed: 17221864
J Breath Res. 2019 Mar 06;13(2):026007
pubmed: 30641506
Br J Haematol. 2016 Feb;172(4):512-23
pubmed: 26491866
Blood. 2016 Sep 22;128(12):1555-61
pubmed: 27412888
Adv Nutr. 2017 Jan 17;8(1):126-136
pubmed: 28096133
Blood. 2015 Apr 23;125(17):2597-604
pubmed: 25733580
Ann N Y Acad Sci. 2010 Aug;1202:134-40
pubmed: 20712784
Orphanet J Rare Dis. 2017 May 18;12(1):93
pubmed: 28521805
Mediterr J Hematol Infect Dis. 2017 Apr 15;9(1):e2017031
pubmed: 28512560
Blood. 2012 Jul 12;120(2):473-6
pubmed: 22645178
Blood. 2012 Feb 2;119(5):1107-16
pubmed: 22096239
Int J Mol Sci. 2014 May 19;15(5):8835-45
pubmed: 24857915
J Clin Invest. 2011 Dec;121(12):4880-8
pubmed: 22045566
J Biol Inorg Chem. 2008 Jan;13(1):57-74
pubmed: 17906879
Br J Haematol. 2011 Mar;152(5):512-23
pubmed: 21250971
Blood Cells Mol Dis. 2018 May;70:54-65
pubmed: 28651846
Haematologica. 2014 Feb;99(2):267-75
pubmed: 23975182
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Haematologica. 2014 May;99(5):811-20
pubmed: 24790059
Blood. 2018 Oct 25;132(17):1781-1791
pubmed: 30206117
Turk J Haematol. 2004 Sep 5;21(3):137-9
pubmed: 27264081
Orphanet J Rare Dis. 2010 May 21;5:11
pubmed: 20492708
World J Hepatol. 2010 May 27;2(5):171-4
pubmed: 21160991
Biomed Rep. 2016 Jun;4(6):728-736
pubmed: 27284414
Biochim Biophys Acta. 2012 Mar;1820(3):403-10
pubmed: 21855608
J Biol Chem. 2012 Oct 5;287(41):34032-43
pubmed: 22898811
Int J Mol Sci. 2018 Dec 17;19(12):
pubmed: 30562917
Blood. 2011 Mar 10;117(10):2817-26
pubmed: 21156846
Ann Surg. 2005 Feb;241(2):208-16
pubmed: 15650628
PLoS One. 2018 Dec 6;13(12):e0208316
pubmed: 30521599
Ann N Y Acad Sci. 2005;1054:18-24
pubmed: 16339647
Am J Clin Pathol. 2009 Oct;132(4):643; author reply 644
pubmed: 19762541
Cureus. 2019 Aug 22;11(8):e5465
pubmed: 31641562
Curr Opin Hematol. 2015 May;22(3):199-205
pubmed: 25710710
Prenat Diagn. 2007 Feb;27(2):150-3
pubmed: 17186566
Blood. 2011 Feb 3;117(5):1745-50
pubmed: 21119108
Mol Neurodegener. 2016 May 17;11(1):39
pubmed: 27184028
Hemoglobin. 2012;36(5):485-90
pubmed: 22738610
Scand J Clin Lab Invest. 2007;67(1):11-25
pubmed: 17365982
Indian J Hematol Blood Transfus. 2017 Dec;33(4):552-558
pubmed: 29075068
Mediterr J Hematol Infect Dis. 2014 Apr 07;6(1):e2014025
pubmed: 24803998
J Blood Med. 2015 Feb 19;6:69-85
pubmed: 25737641
Biotechnol Lett. 2016 Aug;38(8):1243-50
pubmed: 27075690
Curr Med Chem. 2019;26(2):288-301
pubmed: 28933303
Toxicol Appl Pharmacol. 2019 Nov 1;382:114748
pubmed: 31499193
Exp Biol Med (Maywood). 2015 Aug;240(8):1050-64
pubmed: 26283707
Open Access Maced J Med Sci. 2017 Jun 03;5(3):324-331
pubmed: 28698751
Mol Genet Genomic Med. 2021 Dec;9(12):e1788
pubmed: 34738740
Mediterr J Hematol Infect Dis. 2019 Mar 01;11(1):e2019019
pubmed: 30858957
Br J Haematol. 2004 Sep;126(6):881-4
pubmed: 15352994
Pharmaceuticals (Basel). 2019 Sep 17;12(3):
pubmed: 31533229
Ann N Y Acad Sci. 2010 Aug;1202:1-9
pubmed: 20712765
Blood Cells Mol Dis. 2015 Aug;55(2):104-7
pubmed: 26142324
Blood. 2010 Jun 3;115(22):4331-6
pubmed: 20233970
Thromb Res. 2016 Oct;146:35-42
pubmed: 27572718
PLoS One. 2013 Nov 14;8(11):e81820
pubmed: 24244748
Ann N Y Acad Sci. 2010 Aug;1202:237-43
pubmed: 20712799
Clin Appl Thromb Hemost. 2015 Nov;21(8):733-44
pubmed: 24989711
Blood. 2018 Feb 1;131(5):505-514
pubmed: 29141943